治験レーダーAI | ||
|---|---|---|
治験 NCT04854135 (CGM4Home)(対象:1型糖尿病、2型糖尿病、高血糖、低血糖、無自覚性低血糖)は中止です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。 | ||
フィルター基準に一致する試験が1件見つかりました
タイル表示
Continuous Glucose Monitoring Initiation at Hospital Discharge (CGM4Home) 20
治験(臨床試験)の詳細は主に英語で提供されていますが、治験レーダーAIがサポートします!「治験解説」をクリックして、選択した言語で試験情報を表示し、議論してください。
治験番号 NCT04854135 (CGM4Home) は 介入研究 臨床試験 で、1型糖尿病、2型糖尿病、高血糖、低血糖、無自覚性低血糖 に関するものです。現在は 中止 で、2021年4月13日 から開始しています。20 名の参加者 の募集が計画されています。この試験は セントルイスのワシントン大学 によって主導され、2022年6月13日 に完了予定です。ClinicalTrials.gov からの最新更新日は 2024年2月16日 です。
概要
The purpose of this study is to look at feasibility (the likelihood) of continued use of the FreeStyle Libre 2 Continuous glucose monitor (CGM) when started at the time of hospital discharge in patients with poorly controlled diabetes and to look at the effects of CGM use on blood glucose control and quality of life. Additional information will be collected to determine the barriers to continuing CGM use after discha...もっと見る
詳細説明
VISIT/PHONE CALL WHAT WILL HAPPEN? (estimated time) \[window\]
Screening Visit (~45 minutes) Review consent form and obtain consent Complete questionnaire, obtain diabetes history Day of Discharge (~1 hour) Complete FreeStyle Libre 2 CGM education Attach FreeStyle Libre 2 CGM sensor to arm Within 1-3 weeks from discharge Phone Call (~30 minutes) Questions regarding use of FreeStyle Libre 2 CGM Current diabetes re...
もっと見る公式タイトル
Continuous Glucose Monitoring Initiation at Hospital Discharge: A Feasibility Pilot Study
疾患名
1型糖尿病2型糖尿病高血糖低血糖無自覚性低血糖刊行物
この臨床試験について発表された科学記事と研究論文:その他の研究識別子
- CGM4Home
- 202101175
主目的
支持療法
割付方法
該当なし
介入モデル
単一群割当
盲検化
なし(非盲検)
群(アーム)/介入
| 参加グループ/群 | 介入/治療法 |
|---|---|
実験的CGM Intervention All eligible patients will receive a Continuous Glucose Monitor (CGM) prior to hospital discharge after signing an informed consent. | CGM4Home FreeStyle Libre 2 Continuous Glucose Monitoring System manufactured by Abbott |
主要評価項目
副次評価項目
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
To Determine the Feasibility of Initiating a Continuous Glucose Monitoring in Patients With Diabetes at Hospital Discharge | Starting and continuing to use a CGM at this critical time is feasible. Feasibility is defined as at least 20 percent of patients with diabetes referred for diabetes education meet inclusion criteria to participate and at least 75 percent participate. From those who participate, at least 50 percent continue using the CGM at 3 months. | At 3 months |
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
Percentage of Patients That Discontinue the CGM | Discontinuation rate, measured by percentage of patients that discontinue the CGM at 6 months with wearing device, use, costs, getting refills, etc.) | At 6 months |
Mean Time in Range Outcomes | Mean and SD of Time below target, in target and above target at 1 month and 3 months | At 1 month and 3 months |
Mean Change in Self-efficacy at 3 Months | Using the Diabetes self-management Questionnaire (DMSQ), the investigators will measure the mean change and SD in the score (pre- and post- intervention)
score is 0-48, higher scores mean a better outcome | Baseline and 3 months |
適格基準
対象年齢
成人, 高齢者
試験の最低年齢
18 Years
対象性別
全て
- 18 years of age or older
- Have diabetes (type 1 diabetes mellitus, type 2 diabetes mellitus, cystic fibrosis related diabetes mellitus)
- Hemoglobin A1c greater than or equal to 8.0% or history of hypoglycemia unawareness
- Able and willing to sign informed consent form
- Have a valid telephone number
- Willing to purchase FreeStyle Libre 2 CGM sensors out of pocket after discharge from hospital (when insurance coverage isn't available)
- Unable to sign informed consent form
- Have altered mental status
- Unable to manage diabetes independently at home
- Have utilized CGM in the past
- Pregnancy
- New steroid-induced hyperglycemia
- Unwilling to participate in the study
- Have kidney disease requiring hemodialysis
- Taking high doses of vitamin C daily (greater than 500 mg every day)
責任者
Paulina Cruz Bravo, 主任研究者, Assistant Professor of Medicine, Washington University School of Medicine
連絡先情報がありません。
1 1カ国の場所
Missouri
Barnes Jewish Hospital/ Washington University, St Louis, Missouri, 63110, United States